Company profile
Tiziana Life Sciences Ltd
NASDAQ:TLSABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| FORALUMAB | phase2 | — | 7 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06868628 | phase2 | recruiting | 2025-05-19 | 2027-04-01 | Tiziana Life Sciences LTD | A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) |
| NCT06292923 | phase2 | active_not_recruiting | 2023-11-15 | 2026-09-01 | Tiziana Life Sciences LTD | A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients |
| NCT05028946 | phase1 | withdrawn | 2022-05-01 | 2023-07-07 | Tiziana Life Sciences LTD | A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease |
| NCT03291249 | phase2 | withdrawn | 2017-12-01 | 2018-12-01 | Tiziana Life Sciences LTD | Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM |
| NCT04983446 | phase2 | withdrawn | 2022-04-30 | 2022-10-30 | Tiziana Life Sciences LTD | In-patient COVID-19 Study of Intranasal Foralumab |
FDA applications (0)
No records yet.